FDA Approves Lucentis Biosimilar Nufymco
-
By
-
Conexiant News Staff
-
January 2, 2026
-
1 min
By
Conexiant News Staff
January 2, 2026
A US systematic review found substantial losses across diabetic retinopathy screening, diagnosis awareness, referral, and follow-up.
June 25, 2026
A nationally representative US cohort identified a contrast sensitivity threshold associated with self-reported visual disability.
July 7, 2026